Another possible limitation of the present study is the unavailability of kinetic data on serum GGT apart from two studies of RCC, which assessed relative changes in serum GGT at a single time point after either radical nephrectomy or nivolumab therapy [11,12]. The gene discussed is GGT1; the disease is renal cell carcinoma.